Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors

Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors

US Patent 10668149 · Granted Jun 2, 2020

Estimated economic value: $119,685,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of 2025
Anti-CD38 antibodies for treatment of acute myeloid leukemia2025
Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use t2025
Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-pos2024
Combination therapies with anti-CD38 antibodies2024
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia2023
Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of 2022
Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of 2022
Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of 2021
Immune modulation and treatment of solid tumors with antibodies that specificall2021
Immune modulation and treatment of solid tumors with antibodies that specificall2021
Combination therapies with anti-CD38 antibodies2020